000 08065cam a2200985 a 4500
001 ocn801405277
003 OCoLC
005 20220711175329.0
006 m o d
007 cr cnu---unuuu
008 120723s2008 enka ob 001 0 eng d
010 _z 2009277297
040 _aN$T
_beng
_epn
_cN$T
_dE7B
_dOCLCQ
_dOCLCE
_dOCLCQ
_dNLGGC
_dYDXCP
_dEBLCP
_dIDEBK
_dDEBSZ
_dOCLCQ
_dCUV
_dOCLCQ
_dD6H
_dAZK
_dUKOUP
_dAGLDB
_dMOR
_dCCO
_dPIFAG
_dZCU
_dOCLCQ
_dMERUC
_dOCLCQ
_dU3W
_dSTF
_dOCLCF
_dOCLCO
_dVNS
_dWRM
_dOCLCQ
_dVTS
_dCOCUF
_dNRAMU
_dICG
_dINT
_dVT2
_dTOF
_dOCLCO
_dAU@
_dOCLCO
_dOCLCQ
_dWYU
_dOCLCO
_dOCLCA
_dREC
_dOCLCQ
_dOCLCO
_dDKC
_dOCLCO
_dOCLCQ
_dCEF
_dUX1
_dOCLCQ
_dHS0
_dUWK
_dADU
_dLIP
_dOCLCQ
_dOCLCA
_dOCLCQ
_dOCLCA
_dUKCRE
_dAJS
_dOCLCQ
_dOCLCO
_dCNNOR
_dOCLCQ
_dREDDC
_dOCLCO
015 _aGBA898115
_2bnb
016 7 _a014691058
_2Uk
019 _a664763575
_a681553825
_a801363553
_a961629833
_a962647980
_a967267761
_a978671446
_a978898472
_a988493085
_a991986815
_a1016977064
_a1018056497
_a1037680991
_a1038046306
_a1038671137
_a1042912192
_a1043657241
_a1045493288
_a1047923607
_a1053530757
_a1055317289
_a1065415915
_a1065943574
_a1080551323
_a1081225048
_a1100827629
_a1101711071
_a1109347794
_a1110384225
_a1112838591
_a1119028015
_a1119105759
_a1120898120
_a1135590499
_a1153501206
_a1157968374
_a1162193876
_a1178722048
_a1183975397
_a1228600262
_a1249173083
_a1257358611
_a1257372835
_a1290079556
_a1297041316
_a1300542608
020 _a9780191548970
_q(electronic bk.)
020 _a0191548979
_q(electronic bk.)
020 _a9780191768583
020 _a0191768588
020 _a1283581272
020 _a9781283581271
020 _a9786613893727
020 _a6613893722
020 _z9780199208166
020 _z0199208166
029 1 _aAU@
_b000051582975
029 1 _aAU@
_b000062595774
029 1 _aDEBBG
_bBV043168821
029 1 _aDEBBG
_bBV044167238
029 1 _aDEBSZ
_b421395710
029 1 _aDEBSZ
_b431184844
029 1 _aNZ1
_b14694029
035 _a(OCoLC)801405277
_z(OCoLC)664763575
_z(OCoLC)681553825
_z(OCoLC)801363553
_z(OCoLC)961629833
_z(OCoLC)962647980
_z(OCoLC)967267761
_z(OCoLC)978671446
_z(OCoLC)978898472
_z(OCoLC)988493085
_z(OCoLC)991986815
_z(OCoLC)1016977064
_z(OCoLC)1018056497
_z(OCoLC)1037680991
_z(OCoLC)1038046306
_z(OCoLC)1038671137
_z(OCoLC)1042912192
_z(OCoLC)1043657241
_z(OCoLC)1045493288
_z(OCoLC)1047923607
_z(OCoLC)1053530757
_z(OCoLC)1055317289
_z(OCoLC)1065415915
_z(OCoLC)1065943574
_z(OCoLC)1080551323
_z(OCoLC)1081225048
_z(OCoLC)1100827629
_z(OCoLC)1101711071
_z(OCoLC)1109347794
_z(OCoLC)1110384225
_z(OCoLC)1112838591
_z(OCoLC)1119028015
_z(OCoLC)1119105759
_z(OCoLC)1120898120
_z(OCoLC)1135590499
_z(OCoLC)1153501206
_z(OCoLC)1157968374
_z(OCoLC)1162193876
_z(OCoLC)1178722048
_z(OCoLC)1183975397
_z(OCoLC)1228600262
_z(OCoLC)1249173083
_z(OCoLC)1257358611
_z(OCoLC)1257372835
_z(OCoLC)1290079556
_z(OCoLC)1297041316
_z(OCoLC)1300542608
037 _nTitle subscribed to via ProQuest Academic Complete
042 _adlr
050 4 _aQH345
_b.H348 2008eb
060 4 _a2009 C-448
060 4 _aQW 630
_bH2356 2008
072 7 _aMED
_x071000
_2bisacsh
082 0 4 _a615.7
_222
049 _aMAIN
245 0 4 _aThe handbook of biological therapy :
_ba guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology /
_cBruce Kirkham [and others].
260 _aOxford :
_bOxford University Press,
_c2008.
300 _a1 online resource (xiv, 155 pages) :
_billustrations
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _adata file
504 _aIncludes bibliographical references and index.
588 0 _aPrint version record.
506 _3Use copy
_fRestrictions unspecified
_2star
_5MiAaHDL
533 _aElectronic reproduction.
_b[Place of publication not identified] :
_cHathiTrust Digital Library,
_d2010.
_5MiAaHDL
538 _aMaster and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
_uhttp://purl.oclc.org/DLF/benchrepro0212
_5MiAaHDL
583 1 _adigitized
_c2010
_hHathiTrust Digital Library
_lcommitted to preserve
_2pda
_5MiAaHDL
505 0 _aPreface; Foreword; Contents; TNF -- tumour necrosis factor [alpha]; Mode of action of anti-TNF; TNF-blocking drugs in clinical use; TNF-blocking drugs not in clinical use; Section 1 TNF-blocker safety; Increased risk of infection; Tuberculosis; Opportunistic infections; Injection-site reactions; Allergic, hypersensitivity reactions, anaphylactic responses; Psoriasis; Infusion reactions (infliximab); Malignancy and lymphoproliferative conditions; Drug-induced lupus-like reactions; Anti-drug antibodies (immunogenicity); Congestive heart failure; Neurological; Hepatobiliary; Use in pregnancy; Lactation.
505 8 _aRespiratoryVaccinations; Use of TNF-blockers with other medications; Haematological; Postmarketing safety experience in Crohn's disease; Section 2 Rheumatology; Rheumatoid arthritis; Other rheumatological conditions; TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis; Ankylosing spondylitis; Psoriatic arthritis; Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade); Certolizumab pegol (Cimzia); Abatacept (Orencia); Anakinra (Kineret); B-cell depletion: Rituximab (Rituxan® [USA], MabThera® [Europe, Asia, South America]); Section 3 Dermatology; Psoriasis.
505 8 _aApproaches to managementAssessing disease severity; Important differences between psoriasis and rheumatoid arthritis; Biological therapy for psoriasis; Etanercept (Enbrel); Infliximab (Remicade); Adalimumab (Humira); Efalizumab (Raptiva); Alefacept (Amevive); Section 4 Gastroenterology; Biological therapy in inflammatory bowel disease and Crohn's disease; Adalimumab (Humira); Infliximab (Remicade); Natalizumab (Tysabri); Certolizumab pegol (Cimzia); Index; A; B; C; D; E; G; H; I; K; L; M; N; O; P; R; S; T; U; V.
520 _aDrugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitionersusing biologics. As the use of these drugs increases around the world, so the level of information needed by primary.
546 _aEnglish.
590 _aeBooks on EBSCOhost
_bEBSCO eBook Subscription Academic Collection - Worldwide
650 0 _aBiological products
_xTherapeutic use.
_9313788
650 0 _aTumor necrosis factor
_xInhibitors.
_9313789
650 1 2 _aTumor Necrosis Factor-alpha
_xtherapeutic use
_9883265
650 2 2 _aGastrointestinal Diseases
_xtherapy
_9883266
650 2 2 _aRheumatic Diseases
_xtherapy
_9883267
650 2 2 _aSkin Diseases
_xtherapy
_9883268
650 2 _aBiological Therapy
_9883269
650 6 _aBiothérapie.
_9883270
650 6 _aTractus gastro-intestinal
_xMaladies
_xTraitement.
_9883271
650 7 _aMEDICAL
_xPharmacology.
_2bisacsh
_9849387
650 7 _aBiological products
_xTherapeutic use.
_2fast
_0(OCoLC)fst00832305
_9313788
655 4 _aElectronic books.
700 1 _aKirkham, Bruce.
_9313790
776 0 8 _iPrint version:
_tHandbook of biological therapy.
_dOxford : Oxford University Press, 2008
_z9780199208166
_w(DLC) 2009277297
_w(OCoLC)233545995
856 4 0 _uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467497
938 _aProQuest Ebook Central
_bEBLB
_nEBL975668
938 _aebrary
_bEBRY
_nebr10581739
938 _aEBSCOhost
_bEBSC
_n467497
938 _aProQuest MyiLibrary Digital eBook Collection
_bIDEB
_n389372
938 _aOxford University Press USA
_bOUPR
_nEDZ0000128785
938 _aYBP Library Services
_bYANK
_n12890309
938 _aYBP Library Services
_bYANK
_n9315947
994 _a92
_bINOPJ
999 _c2736719
_d2736719